SAN DIEGO--(BUSINESS WIRE)--Halozyme Therapeutics, Inc. (Nasdaq:HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced its participation in the UBS Global Life Sciences Conference to be held on September 21-23, 2009 in New York City. Jonathan Lim, M.D., President and CEO, is scheduled to present an overview of Halozyme and its product development pipeline on Tuesday, September 22, 2009 at 3:00 p.m. EDT (12:00 p.m. PDT).
